Finance entity
Every one of those 1 sits in a single category, earnings. Joe Ciaffoni is most often covered alongside Belbuca, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 6.2 in the same window.
Last mentioned: Feb 27, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, earnings. Joe Ciaffoni is most often covered alongside Belbuca, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 6.2 in the same window. Each story carries 2 original sources on average, compared with 3.2 for the broader beat in this window. Joe Ciaffoni appears in 1 tracked Finance story from February 27, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 91 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Joe Ciaffoni. Shared-story counts are live from our verified record — not editorial picks.
CRA International (CRAI) and Collegium Pharmaceutical (COLL) both reported strong Q4 2025 results, highlighting a robust environment for specialized consulting and chronic pain management. While CRAI benefited from record headcount and high utilization in antitrust and litigation, Collegium demonstrated the continued commercial durability of its Belbuca and Xtampza ER franchises.
Joe Ciaffoni is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
